Literature DB >> 34120612

Biomimetic black phosphorus quantum dots-based photothermal therapy combined with anti-PD-L1 treatment inhibits recurrence and metastasis in triple-negative breast cancer.

Peiqi Zhao1, Yuanlin Xu2, Wei Ji3, Shiyong Zhou4, Lanfang Li4, Lihua Qiu4, Zhengzi Qian4, Xianhuo Wang4, Huilai Zhang5.   

Abstract

BACKGROUND: Triple-negative breast cancer (TNBC) is a highly aggressive malignant disease with a high rate of recurrence and metastasis, few effective treatment options and poor prognosis. Here, we designed and constructed a combined photothermal immunotherapy strategy based on cancer cell membrane-coated biomimetic black phosphorus quantum dots (BBPQDs) for tumor-targeted photothermal therapy and anti-PD-L1 mediated immunotherapy.
RESULTS: BBPQDs have good photothermal conversion efficiency and can efficiently target tumor cells through homologous targeting and tumor homing. Under near infrared irradiation, we found that BBPQDs kill tumors directly through photothermal effects and induce dendritic cells maturation. In vivo studies have confirmed that the combined photothermal immunotherapy strategy displays a stronger antitumor activity than anti-PD-L1 monotherapy. In addition, BBPQDs-mediated photothermal therapy in combination with anti-PD-L1 treatment inhibit tumor recurrence and metastasis by reprograming the immunosuppressive tumor microenvironment into an immune-active microenvironment, and promoting the local and systemic antitumor immune response. We further found that the combined photothermal immunotherapy strategy can produce an immune memory effect against tumor rechallenge.
CONCLUSIONS: This study provides a novel therapeutic strategy for inhibiting the recurrence and metastasis of TNBC, with broad application prospects.

Entities:  

Keywords:  Anti-PD-L1; Biomimetic black phosphorus quantum dots; Photothermal immunotherapy; Triple-negative breast cancer; Tumor recurrence and metastasis

Year:  2021        PMID: 34120612     DOI: 10.1186/s12951-021-00932-2

Source DB:  PubMed          Journal:  J Nanobiotechnology        ISSN: 1477-3155            Impact factor:   10.435


  47 in total

Review 1.  Triple-negative breast cancer: an unmet medical need.

Authors:  Clifford A Hudis; Luca Gianni
Journal:  Oncologist       Date:  2011

Review 2.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

3.  Triple-negative breast cancer: clinical features and patterns of recurrence.

Authors:  Rebecca Dent; Maureen Trudeau; Kathleen I Pritchard; Wedad M Hanna; Harriet K Kahn; Carol A Sawka; Lavina A Lickley; Ellen Rawlinson; Ping Sun; Steven A Narod
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

4.  Breast cancer statistics, 2015: Convergence of incidence rates between black and white women.

Authors:  Carol E DeSantis; Stacey A Fedewa; Ann Goding Sauer; Joan L Kramer; Robert A Smith; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-10-29       Impact factor: 508.702

5.  [Resistance of Mycobacterium leprae to sulfones (DDS) and rifampicin in recurring lepromatous leprosy in Martinique and Guadeloupe since February 1980].

Authors:  C C Guelpa-Lauras; M Constant-Desportes; J Millan; J Grosset
Journal:  Acta Leprol       Date:  1982 Jan-Jun

6.  Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.

Authors:  S Adams; P Schmid; H S Rugo; E P Winer; D Loirat; A Awada; D W Cescon; H Iwata; M Campone; R Nanda; R Hui; G Curigliano; D Toppmeyer; J O'Shaughnessy; S Loi; S Paluch-Shimon; A R Tan; D Card; J Zhao; V Karantza; J Cortés
Journal:  Ann Oncol       Date:  2019-03-01       Impact factor: 32.976

Review 7.  Triple negative breast cancers: clinical and prognostic implications.

Authors:  S J Dawson; E Provenzano; C Caldas
Journal:  Eur J Cancer       Date:  2009-09       Impact factor: 9.162

Review 8.  The fate of chemoresistance in triple negative breast cancer (TNBC).

Authors:  Elma A O'Reilly; Luke Gubbins; Shiva Sharma; Riona Tully; Matthew Ho Zhing Guang; Karolina Weiner-Gorzel; John McCaffrey; Michele Harrison; Fiona Furlong; Malcolm Kell; Amanda McCann
Journal:  BBA Clin       Date:  2015-03-12

9.  Triple Negative Breast Cancer - An Overview.

Authors:  Kartik Aysola; Akshata Desai; Crystal Welch; Jingyao Xu; Yunlong Qin; Vaishali Reddy; Roland Matthews; Charlotte Owens; Joel Okoli; Derrick J Beech; Chandrika J Piyathilake; Shyam P Reddy; Veena N Rao
Journal:  Hereditary Genet       Date:  2013

10.  Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.

Authors:  Luc Y Dirix; Istvan Takacs; Guy Jerusalem; Petros Nikolinakos; Hendrik-Tobias Arkenau; Andres Forero-Torres; Ralph Boccia; Marc E Lippman; Robert Somer; Martin Smakal; Leisha A Emens; Borys Hrinczenko; William Edenfield; Jayne Gurtler; Anja von Heydebreck; Hans Juergen Grote; Kevin Chin; Erika P Hamilton
Journal:  Breast Cancer Res Treat       Date:  2017-10-23       Impact factor: 4.872

View more
  7 in total

1.  Biomimetic doxorubicin/ginsenoside co-loading nanosystem for chemoimmunotherapy of acute myeloid leukemia.

Authors:  Mo Chen; Yingyu Qiao; Jie Cao; Tianyuan Ci; Xue Ke
Journal:  J Nanobiotechnology       Date:  2022-06-14       Impact factor: 9.429

Review 2.  Potential of Black Phosphorus in Immune-Based Therapeutic Strategies.

Authors:  Wenjuan Dong; Hu Wang; Hailin Liu; Chunqiao Zhou; Xuelin Zhang; Song Wang; Lin He
Journal:  Bioinorg Chem Appl       Date:  2022-07-11       Impact factor: 4.724

3.  Selectively down-regulated PD-L1 by albumin-phenformin nanoparticles mediated mitochondrial dysfunction to stimulate tumor-specific immunological response for enhanced mild-temperature photothermal efficacy.

Authors:  Zaigang Zhou; Ning Jiang; Jiashe Chen; Chunjuan Zheng; Yuanyuan Guo; Ruirong Ye; Ruogu Qi; Jianliang Shen
Journal:  J Nanobiotechnology       Date:  2021-11-18       Impact factor: 10.435

Review 4.  Nanomedicines for Overcoming Cancer Drug Resistance.

Authors:  Tingting Hu; Hanlin Gong; Jiayue Xu; Yuan Huang; Fengbo Wu; Zhiyao He
Journal:  Pharmaceutics       Date:  2022-08-01       Impact factor: 6.525

Review 5.  Cell membrane coated-nanoparticles for cancer immunotherapy.

Authors:  Yingping Zeng; Sufen Li; Shufen Zhang; Li Wang; Hong Yuan; Fuqiang Hu
Journal:  Acta Pharm Sin B       Date:  2022-02-28       Impact factor: 14.903

Review 6.  Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: A review of current developments.

Authors:  Qi Jiang; Mixue Xie; Ruyin Chen; Feifei Yan; Chanqi Ye; Qiong Li; Shuaishuai Xu; Wei Wu; Yunlu Jia; Peng Shen; Jian Ruan
Journal:  Front Immunol       Date:  2022-08-29       Impact factor: 8.786

7.  Multifunctional PEGylated Niosomal Nanoparticle-Loaded Herbal Drugs as a Novel Nano-Radiosensitizer and Stimuli-Sensitive Nanocarrier for Synergistic Cancer Therapy.

Authors:  Saeid Afereydoon; Fateme Haghiralsadat; Nima Hamzian; Ali Shams; Mahdie Hemati; Seyed Morteza Naghib; Masoud Shabani; Behrouz Zandieh-Doulabi; Davood Tofighi
Journal:  Front Bioeng Biotechnol       Date:  2022-08-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.